23 Jul 2025
At the 2024 Market Access Summit on October 29, Guillaume Couillard, Director General, presented an update on the Patented Medicine Prices Review Board (PMPRB), its evolving mandate, and the development of new guidelines to ensure Canada’s patented drug prices remain fair and transparent. Key Points Mandate: Established in 1987 under the Patent Act as an […]
07 Apr 2025
The Canadian drug landscape is undergoing a transformative shift, and pharmaceutical manufacturers need a strategic playbook to succeed. Here are seven insider secrets to help you navigate the Canada’s Drug Agency’s (CDA) new mandate: 1. Embrace Real-World Evidence Early Gone are the days of relying solely on clinical trial data. The CDA now actively […]
07 Apr 2025
In a recent panel discussion on pharmaceutical access, healthcare experts revealed critical insights into how technology could revolutionize healthcare equity. Here are four groundbreaking trends that promise to reshape how Canadians access medical care: Intelligent Telehealth Beyond Urban Centers The days of one-size-fits-all telehealth are over. Emerging technologies are now focusing on: Satellite internet solutions […]
22 May 2025
The introduction of Canada’s national PharmaCare program has created a complex environment for pharmaceutical companies developing innovative medicines. Here are three strategic approaches to navigate this uncertain terrain: Proactive Engagement with Policy Makers As the landscape of healthcare continues to evolve, proactive engagement with policymakers has become essential for innovative pharmaceutical companies. The current PharmaCare […]
19 Jun 2025
Introduction In the rapidly evolving landscape of Canadian healthcare, biosimilars are emerging as a game-changing solution to rising medical costs. With the total biologics market valued at $8 billion and biosimilars representing $1 billion, these innovative medications are reshaping how we approach treatment and healthcare spending. Unprecedented Cost Savings BC has saved $700 million […]
07 Apr 2025
In the rapidly evolving landscape of healthcare innovation, breakthrough therapies are emerging faster than ever—but there’s a critical bottleneck preventing patients from accessing these life-changing treatments. Enter Outcome-Based Agreements (OBAs), a strategic approach that’s poised to transform how we think about pharmaceutical access and value. 1. Accelerating Time to Patient Access Traditional reimbursement processes in […]
22 May 2025
The COVID-19 pandemic was a crucible of innovation, challenge, and transformation for healthcare systems worldwide. Quebec’s INESSS has emerged with critical insights that are reshaping healthcare strategy. Here are five key lessons learned: Adaptability is Essential The pandemic demonstrated that healthcare systems must be nimble. INESSS’s new strategic approach reflects this, with a flexible […]
07 Apr 2025
A Comprehensive Analysis of Systemic Barriers and Transformative Strategies Executive Summary: The healthcare landscape for First Nations communities in Canada represents a critical intersection of technological innovation, policy reform, and social equity. This whitepaper examines the complex challenges and presents actionable solutions to address healthcare access disparities. Introduction: In the vast and diverse landscape […]
09 Jun 2025
Executive Summary The Patented Medicines Prices Review Board (PMPRB) is undergoing a significant transformation in its approach to pharmaceutical pricing guidelines. This white paper explores the comprehensive consultation process that is reshaping the organization’s methodology for monitoring and reviewing drug prices in Canada. Historical Context The PMPRB emerged from the 1987 NAFTA discussions as […]
Loading...
